Sunil Healthcare

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE671C01016
NSEID:
BSEID: 537253

INR

70.00

2.06 (3.03%)

BSENSE

Dec 19

BSE+NSE Vol: 241

{
  "main_header": {
    "sid": 396654,
    "name": "Sunil Healthcare",
    "stock_name": "Sunil Healthcare",
    "full_name": "Sunil Healthcare Ltd",
    "name_url": "stocks-analysis/sunil-healthcare",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "70.00",
    "chg": 2.06,
    "chgp": "3.03%",
    "dir": 1,
    "prev_price": "67.94",
    "mcapval": "70.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 537253,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE671C01016",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "241 ",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sunil-healthcare-396654-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Sunil Healthcare falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sunil-healthcare-fallingrising-3761683",
        "imagepath": "",
        "date": "2025-12-18 00:49:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Price Movement and Market Context</strong></p>\n<p>Sunil Healthcare’s stock price demonstrated a robust upward movement on 17 Dec, gaining ₹5.38 or 8.33% from its previous close. This surge is particularly striking given the stock’s recent downward trend, as it reversed losses sustained over the prior two sessions. The stock opened with a gap up of 2.14%, signalling strong buying interest from the outset of trading. Intraday, the share price touched a high of ₹72, representing an 11.42% increase from the previous day’s close, before settling slightly lower but still maintaining a substantial gain.</p>\n<p>When compared to the broader market, Sunil Healthcare outperformed the Sensex benchmark, which recorded a modest gain of 0.20% over the past week. The stock’s one-week return of 1.52% also su..."
      },
      {
        "title": "Sunil Healthcare’s Market Assessment Revised Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sunil-healthcare-downgraded-to-sell-by-marketsmojo-amid-weak-fundamentals-3749934",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/SunilHealthcare_mojoScore_3749934.png",
        "date": "2025-12-06 10:10:05",
        "description": "Sunil Healthcare has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment. The pharmaceutical and biotechnology microcap’s recent assessment highlights a complex interplay of financial trends, valuation appeal, and technical outlook, set against a backdrop of subdued sector performance and stock returns."
      },
      {
        "title": "Why is Sunil Healthcare falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sunil-healthcare-fallingrising-3702377",
        "imagepath": "",
        "date": "2025-11-14 22:06:59",
        "description": "As of 14-Nov, Sunil Healthcare Ltd's stock price is currently at 72.00, reflecting an increase of 0.27 (0.38%). The stock has recently experienced a trend reversal, gaining after five consecutive days of decline. However, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally bearish trend. Despite this, the company has reported positive financial results, including a 9.89% growth in net profit and strong operating cash flow, which may have contributed to the recent uptick in stock price. Nonetheless, the stock has underperformed significantly over the past year, with a return of -5.26%, and has shown weak long-term fundamental strength, including a low return on capital employed and poor sales growth.\n\nIn the broader market context, the stock's performance over the past week has been notably poor, with a decline of 4.38%, while the benchmark Sensex has i..."
      },
      {
        "title": "Is Sunil Healthcare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sunil-healthcare-overvalued-or-undervalued-3683839",
        "imagepath": "",
        "date": "2025-11-10 08:07:28",
        "description": "As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, with a PE Ratio of 44.63, an EV to EBITDA of 11.04, and a PEG Ratio of 0.19. These ratios suggest that the stock is priced high relative to its earnings growth potential.\n\nIn comparison to its peers, Sun Pharma has a PE Ratio of 35.17 and an EV to EBITDA of 10.65, while Cipla, rated as attractive, has a PE Ratio of 22.33 and an EV to EBITDA of 5.58. These figures highlight that Sunil Healthcare is trading at a premium compared to more attractively valued competitors. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -3.46% compared to the Sensex's 6.50%. This further reinforces the view that Sunil Healthcare may be overvalued in the current marke..."
      },
      {
        "title": "Is Sunil Healthcare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sunil-healthcare-overvalued-or-undervalued-3682626",
        "imagepath": "",
        "date": "2025-11-09 08:07:04",
        "description": "As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19, which suggests that while the stock is expensive relative to earnings, it may offer growth potential at a reasonable price.\n\nIn comparison to its peers, Sunil Healthcare's PE ratio is higher than Sun Pharma Industries, which is considered expensive at 35.17, but lower than Divi's Laboratories, which is very expensive at 71.11. Additionally, Cipla, rated attractive, has a significantly lower PE ratio of 22.33, indicating that Sunil Healthcare may not be the best value in its sector. The company's recent stock performance has lagged behind the Sensex, particularly over the past year, where it has declined by 11.93% compared to a 4.62..."
      },
      {
        "title": "Is Sunil Healthcare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sunil-healthcare-overvalued-or-undervalued-3681753",
        "imagepath": "",
        "date": "2025-11-08 08:06:48",
        "description": "As of 7 November 2025, the valuation grade for Sunil Healthcare has moved from attractive to fair. The company is currently fairly valued. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19. In comparison to peers, Sun Pharma has a PE ratio of 35.17 and is considered expensive, while Cipla, which is rated attractive, has a PE ratio of 22.33.\n\nDespite the recent downgrade in valuation, Sunil Healthcare's stock has shown resilience with a 1-week return of 4.58%, outperforming the Sensex, which had a return of -0.86%. However, over the longer term, the company has underperformed, with a 1-year return of -11.93% compared to the Sensex's 4.62%. This suggests that while the company is currently fairly valued, its long-term performance may warrant further scrutiny...."
      },
      {
        "title": "Are Sunil Healthcare latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-sunil-healthcare-latest-results-good-or-bad-3673868",
        "imagepath": "",
        "date": "2025-11-05 19:13:46",
        "description": "Sunil Healthcare's latest financial results reflect a notable return to profitability after a challenging period marked by consecutive quarterly losses. In Q2 FY26, the company reported a net profit of ₹0.91 crores, a significant turnaround from losses in the previous year. This profit recovery is accompanied by an operating margin of 14.49%, the highest in seven quarters, indicating improved cost management and operational efficiency. Revenue for the quarter stood at ₹22.64 crores, showing a year-on-year growth of 5.30% and a sequential increase of 6.79%.\n\nDespite these positive developments, the company continues to face structural challenges. The average return on capital employed (ROCE) and return on equity (ROE) remain low at 4.61% and 4.96%, respectively, highlighting issues with capital efficiency. Additionally, Sunil Healthcare's debt-to-EBITDA ratio is elevated at 6.87 times, raising concerns about..."
      },
      {
        "title": "How has been the historical performance of Sunil Healthcare?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-sunil-healthcare-3672054",
        "imagepath": "",
        "date": "2025-11-04 22:50:16",
        "description": "Answer:\nThe historical performance of Sunil Healthcare shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nSunil Healthcare's net sales have decreased from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25. The company's total expenditure also declined from 94.33 Cr in Mar'23 to 73.16 Cr in Mar'25, indicating cost management efforts. Operating profit, which reached 20.66 Cr in Mar'23, fell to 11.60 Cr by Mar'25, while profit before tax transitioned from a positive 9.48 Cr in Mar'23 to a negative 1.22 Cr in Mar'25. Consequently, the profit after tax also turned negative, from 6.68 Cr in Mar'23 to -1.42 Cr in Mar'25. The company's total liabilities increased from 120.79 Cr in Mar'23 to 161.94 Cr in Mar'25, while total assets rose from 120.79 Cr to 161...."
      },
      {
        "title": "Sunil Healthcare Q2 FY26: Micro-Cap Pharma Returns to Profit After Three-Quarter Losing Streak",
        "link": "https://www.marketsmojo.com/news/result-analysis/sunil-healthcare-q2-fy26-micro-cap-pharma-returns-to-profit-after-three-quarter-losing-streak-3671912",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SunilHealthcare_quaterlyResult_3671912.png",
        "date": "2025-11-04 21:16:12",
        "description": "Sunil Healthcare Ltd., India's second-largest manufacturer of empty hard gelatin capsules, has reported a net profit of ₹0.91 crores for Q2 FY26, marking a dramatic turnaround from three consecutive quarters of losses. The Alwar-based pharmaceutical company posted a sequential profit growth of 152.78% compared to ₹0.36 crores in Q1 FY26, though it represents a year-on-year decline of 231.88% from a loss of ₹0.69 crores in Q2 FY25. The stock, trading at ₹73.97 with a market capitalisation of ₹77.00 crores, has declined 1.37% following the results announcement."
      }
    ],
    "total": 87,
    "sid": "396654",
    "stock_news_url": "https://www.marketsmojo.com/news/sunil-healthcare-396654"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "06-Nov-2025",
      "details": "Copy of newspaper publication dated 06.11.2025 (both hindi and english) regarding un-audited financial results for the quarter/half year ended 30.09.2025",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results (Both Standalone And Consolidated) For The Quarter/Half Tear Ended 30.09.2025",
      "datetime": "04-Nov-2025",
      "details": "Board of Directors at its meeting held today on 04.11.2025 interalia approved Unaudited Financial results (both standalone and consolidated) for the quarter/half year ended 30.09.2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On 04.11.2025",
      "datetime": "04-Nov-2025",
      "details": "Board of Directors at its meeting held today on 04.11.2025 interalia approved un-audited financial results(both standalone and consolidated) for the quarter/half year ended 30.09.2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Sunil Healthcare falling/rising?

2025-12-18 00:49:06

Price Movement and Market Context

Sunil Healthcare’s stock price demonstrated a robust upward movement on 17 Dec, gaining ₹5.38 or 8.33% from its previous close. This surge is particularly striking given the stock’s recent downward trend, as it reversed losses sustained over the prior two sessions. The stock opened with a gap up of 2.14%, signalling strong buying interest from the outset of trading. Intraday, the share price touched a high of ₹72, representing an 11.42% increase from the previous day’s close, before settling slightly lower but still maintaining a substantial gain.

When compared to the broader market, Sunil Healthcare outperformed the Sensex benchmark, which recorded a modest gain of 0.20% over the past week. The stock’s one-week return of 1.52% also su...

Sunil Healthcare’s Market Assessment Revised Amidst Challenging Fundamentals

2025-12-06 10:10:05

Sunil Healthcare has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment. The pharmaceutical and biotechnology microcap’s recent assessment highlights a complex interplay of financial trends, valuation appeal, and technical outlook, set against a backdrop of subdued sector performance and stock returns.

Why is Sunil Healthcare falling/rising?

2025-11-14 22:06:59

As of 14-Nov, Sunil Healthcare Ltd's stock price is currently at 72.00, reflecting an increase of 0.27 (0.38%). The stock has recently experienced a trend reversal, gaining after five consecutive days of decline. However, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally bearish trend. Despite this, the company has reported positive financial results, including a 9.89% growth in net profit and strong operating cash flow, which may have contributed to the recent uptick in stock price. Nonetheless, the stock has underperformed significantly over the past year, with a return of -5.26%, and has shown weak long-term fundamental strength, including a low return on capital employed and poor sales growth. In the broader market context, the stock's performance over the past week has been notably poor, with a decline of 4.38%, while the benchmark Sensex has i...

Is Sunil Healthcare overvalued or undervalued?

2025-11-10 08:07:28

As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, with a PE Ratio of 44.63, an EV to EBITDA of 11.04, and a PEG Ratio of 0.19. These ratios suggest that the stock is priced high relative to its earnings growth potential. In comparison to its peers, Sun Pharma has a PE Ratio of 35.17 and an EV to EBITDA of 10.65, while Cipla, rated as attractive, has a PE Ratio of 22.33 and an EV to EBITDA of 5.58. These figures highlight that Sunil Healthcare is trading at a premium compared to more attractively valued competitors. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -3.46% compared to the Sensex's 6.50%. This further reinforces the view that Sunil Healthcare may be overvalued in the current marke...

Is Sunil Healthcare overvalued or undervalued?

2025-11-09 08:07:04

As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19, which suggests that while the stock is expensive relative to earnings, it may offer growth potential at a reasonable price. In comparison to its peers, Sunil Healthcare's PE ratio is higher than Sun Pharma Industries, which is considered expensive at 35.17, but lower than Divi's Laboratories, which is very expensive at 71.11. Additionally, Cipla, rated attractive, has a significantly lower PE ratio of 22.33, indicating that Sunil Healthcare may not be the best value in its sector. The company's recent stock performance has lagged behind the Sensex, particularly over the past year, where it has declined by 11.93% compared to a 4.62...

Is Sunil Healthcare overvalued or undervalued?

2025-11-08 08:06:48

As of 7 November 2025, the valuation grade for Sunil Healthcare has moved from attractive to fair. The company is currently fairly valued. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19. In comparison to peers, Sun Pharma has a PE ratio of 35.17 and is considered expensive, while Cipla, which is rated attractive, has a PE ratio of 22.33. Despite the recent downgrade in valuation, Sunil Healthcare's stock has shown resilience with a 1-week return of 4.58%, outperforming the Sensex, which had a return of -0.86%. However, over the longer term, the company has underperformed, with a 1-year return of -11.93% compared to the Sensex's 4.62%. This suggests that while the company is currently fairly valued, its long-term performance may warrant further scrutiny....

Are Sunil Healthcare latest results good or bad?

2025-11-05 19:13:46

Sunil Healthcare's latest financial results reflect a notable return to profitability after a challenging period marked by consecutive quarterly losses. In Q2 FY26, the company reported a net profit of ₹0.91 crores, a significant turnaround from losses in the previous year. This profit recovery is accompanied by an operating margin of 14.49%, the highest in seven quarters, indicating improved cost management and operational efficiency. Revenue for the quarter stood at ₹22.64 crores, showing a year-on-year growth of 5.30% and a sequential increase of 6.79%. Despite these positive developments, the company continues to face structural challenges. The average return on capital employed (ROCE) and return on equity (ROE) remain low at 4.61% and 4.96%, respectively, highlighting issues with capital efficiency. Additionally, Sunil Healthcare's debt-to-EBITDA ratio is elevated at 6.87 times, raising concerns about...

How has been the historical performance of Sunil Healthcare?

2025-11-04 22:50:16

Answer: The historical performance of Sunil Healthcare shows a fluctuating trend in key financial metrics over the years. Breakdown: Sunil Healthcare's net sales have decreased from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25. The company's total expenditure also declined from 94.33 Cr in Mar'23 to 73.16 Cr in Mar'25, indicating cost management efforts. Operating profit, which reached 20.66 Cr in Mar'23, fell to 11.60 Cr by Mar'25, while profit before tax transitioned from a positive 9.48 Cr in Mar'23 to a negative 1.22 Cr in Mar'25. Consequently, the profit after tax also turned negative, from 6.68 Cr in Mar'23 to -1.42 Cr in Mar'25. The company's total liabilities increased from 120.79 Cr in Mar'23 to 161.94 Cr in Mar'25, while total assets rose from 120.79 Cr to 161....

Sunil Healthcare Q2 FY26: Micro-Cap Pharma Returns to Profit After Three-Quarter Losing Streak

2025-11-04 21:16:12

Sunil Healthcare Ltd., India's second-largest manufacturer of empty hard gelatin capsules, has reported a net profit of ₹0.91 crores for Q2 FY26, marking a dramatic turnaround from three consecutive quarters of losses. The Alwar-based pharmaceutical company posted a sequential profit growth of 152.78% compared to ₹0.36 crores in Q1 FY26, though it represents a year-on-year decline of 231.88% from a loss of ₹0.69 crores in Q2 FY25. The stock, trading at ₹73.97 with a market capitalisation of ₹77.00 crores, has declined 1.37% following the results announcement.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication

06-Nov-2025 | Source : BSE

Copy of newspaper publication dated 06.11.2025 (both hindi and english) regarding un-audited financial results for the quarter/half year ended 30.09.2025

Unaudited Financial Results (Both Standalone And Consolidated) For The Quarter/Half Tear Ended 30.09.2025

04-Nov-2025 | Source : BSE

Board of Directors at its meeting held today on 04.11.2025 interalia approved Unaudited Financial results (both standalone and consolidated) for the quarter/half year ended 30.09.2025

Board Meeting Outcome for Outcome Of Board Meeting Held On 04.11.2025

04-Nov-2025 | Source : BSE

Board of Directors at its meeting held today on 04.11.2025 interalia approved un-audited financial results(both standalone and consolidated) for the quarter/half year ended 30.09.2025